Researchers from Brazil developed a new clinical score to estimate the probability of neuromyelitis optica spectrum disorder (NMOSD) in patients presenting with optic neuritis. The easily accessible ...

12. Optic Neuritis Emerging Drugs and Latest Therapeutic Advances 13. Optic Neuritis Seven Major Market Analysis 14. Attribute Analysis 15. Optic Neuritis Market Outlook (In US, EU5, and Japan) 16.

News GlobeNewswire Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond ...

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations ...

Casserly CC, et al. Effect of fampridine SR on individuals with multiple sclerosis and poor recovery from optic neuritis: A pilot study. Presented at: ACTRIMS; Feb. 27-March 1, 2025; West Palm Beach.

Optic neuritis (ON) is an inflammation that damages your optic nerve. It can cause vision loss and pain when you move your eyes. As the inflammation goes away, your symptoms usually get better ...

Acute optic neuritis is a rare condition characterized by an acute inflammation of the optic nerve that can lead to permanent visual impairment. It affects up to 8 in 100,000 people worldwide and ...

A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain, 133 (9), 2592-2602. 5 Petzold, A., and al. (2020).

OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ...

Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in ...

Ophthalmic diseases specialist Oculis Holding AG announced positive phase II data showing its serum-glucose corticoid kinase-2 activator OCS-05 protected nerve cells and improved vision in patients ...

OCS-05 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for acute optic neuritis, a rare condition characterized by acute ...